Anteris Technologies Declines Renewal Of ADAPT Tissue Supply Agreement With 4C Medical, Contract To End June 2026; Termination Does Not Impact Financial Results

On November 26, 2025, Anteris Technologies Global Corp. (the "Company") notified 4C Medical Technologies, Inc. ("4C") that it was not renewing the Second Amended and Restated Supply and License Agreement, as amended (the "Supply Agreement"), between the Company and 4C, which provided for the supply by the Company to 4C of ADAPT® tissue used in 4C's production of medical devices related to transcatheter mitral valve and tricuspid valve regurgitation therapy and granted a limited license to the Company's related sterilization methods in connection with use of ADAPT® tissue by 4C in its production of medical devices.The Supply Agreement had a term expiring on June 1, 2026, at which time it would automatically renew for successive one-year terms unless either party provided written notice of non-renewal 180 days prior thereto. The Company will not incur any early termination penalties in connection with its non-renewal of the Supply Agreement. The termination of this contract does not materially impact on the financial results of the Company.